An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE)

Trial Profile

An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms EVERMORE
  • Sponsors Novartis
  • Most Recent Events

    • 27 Feb 2017 Planned End Date changed from 1 Jun 2016 to 30 Mar 2017.
    • 27 Feb 2017 Planned primary completion date changed from 1 Jun 2016 to 30 Mar 2017.
    • 04 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top